Reprint

Actinomycetes

The Antibiotics Producers

Edited by
September 2020
362 pages
  • ISBN978-3-03936-910-2 (Hardback)
  • ISBN978-3-03936-911-9 (PDF)

This book is a reprint of the Special Issue Actinomycetes: The Antibiotics Producers that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary
Beyond being the most important natural compound source, actinomycetes are the origin of up to two-thirds of all clinically used antibiotics. Currently, new antimicrobials are urgently needed, as infections caused by antibiotic-resistant pathogens are on the rise. In the identification of new antibiotics, many scientists are currently investigating biosynthetic aspects of antibiotic production in actinomycetes. Since the emergence of next-generation sequencing technologies, the field of antibiotics research has experienced a remarkable revival. These bacteria have the potential to produce more antibiotics than previously thought possible. Some antibiotics are produced in standard media, while others require the presence of a specific signaling molecule in the medium. Others, however, are only produced when the native regulation of the biosynthesis gene cluster is overruled. This book covers topics in the field of antibiotic-producing actinomycetes. The following tops are addressed: - Approaches to access novel antibiotic producers for novel natural compounds - Omics and genome mining approaches for the discovery of novel natural compounds - Analyses and genetic engineering of antibiotic biosynthesis - Regulation of the secondary metabolism in actinomycetes
Format
  • Hardback
License
© 2020 by the authors; CC BY licence
Keywords
Streptomyces; biogeography; comparative genomics; diversification; secondary metabolite biosynthetic gene clusters; SMGC; natural products; streptomyces; rishirilide; biosynthesis; polyketides; polynucleotide phosphorylase; Streptomyces; ribonuclease; regulation; promoter; RNA decay; polyadenylation; (p)ppGpp; antibiotic; antibiotics; geomicrobiology; Illumina sequencing; microbiome diversity; Streptomyces; Actinobacteria; Cave microbiology; secondary metabolite; antibiotics; rare Actinobacteria; Streptomyces; Amycolatopsis; unculturability; siderophore; glycopeptide antibiotics; dbv cluster; regulatory genes; StrR; LAL; LuxR solo; dalbavancin; A40926; Streptomyces lividans; secretion pathways; secretory proteins; signal peptides; actinomycetes; glycopeptide antibiotics; teicoplanin; A40926; van resistance genes; Streptomyces tsukubaensis; tacrolimus; FK506; omics; streptomyces; screening; antibiotics; secondary metabolism; differentiation; elicitors; morphology; liquid cultures; metagenomics; rare actinomycetes; dereplication; metabolomics; genome mining; natural products; actinomycetes; secondary metabolites; novel compounds; physicochemical screening; physical and chemical properties; structural diversity; biological activity; Actinoallomurus; antibiotics polyethers; screening; lysolipin; minimal PKS II; cyclases; benz[a]naphthacene quinone; tridecaketide; aromatic polyketide; pentacyclic angular polyphenol; extended polyketide chain; actinobacteria; β-lactamase; resistance; antibiotic; β-lactamase inhibitor; natural products; polyketides; polyketide synthases; acyltransferases; engineering; new bioactive compounds; actinobacteria; symbiosis; secondary metabolites; drug discovery; chemical ecology; actinomycetes; antibiotics; secondary metabolism; culture-based approaches; omics; Streptomyces; strain; specialized metabolites; biosynthetic gene cluster; n/a